We are live on ! Find out more

Aclarion

ACON

Market cap $6.86M

2.38 USD

-0.06

2.46%

At close Updated Sep 29, 4:00 PM EDT

1 day

-2.46%

5 days

-7.39%

1 month

1.28%

3 months

-17.65%

6 months

-22.73%

Year to date

-52.21%

1 year

-68.81%

5 years

-100%

10 years

-100%

About: Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.

Employees: 11

Healthcare Health Information Services

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 87.5%

Negative 12.5%

Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites

NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical research CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced NYU Langone Health as a new clinical site in its CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial.

Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites

Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site

University of Arizona College of Medicine – Phoenix is home to a leading neurosurgery and orthopedic spine program with deep expertise in complex spine surgery and a strong commitment to clinical research and innovation Ten sites now actively enrolling in CLARITY study, a prospective, randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the University of Arizona College of Medicine - Phoenix as a new clinical site in its CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial.

Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site

Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers Extends Aclarion's IP protection to over 65 issued and pending patents worldwide, complementing its broader portfolio covering spectroscopy acquisition, data processing, biomarkers and analytics BROOMFIELD, Colo., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for U.S. Patent Application titled “Multi-Voxel Prescription for Lumbar Disc Evaluation.

Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

Zacks Investment Research

Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates

Aclarion, Inc. (ACON) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $2.75 per share a year ago.

Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates

Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology

Partnership brings Nociscan for chronic low back pain to one of the nation's leading neurosurgery and spine care networks Goodman Campbell Brain & Spine is recognized nationally for its role in neurosurgery training and clinical research Availability of Nociscan in Indiana reflects Company's focus on expansion and adding to its growing base of provider sites across the country BROOMFIELD, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, marking the first site in Indiana to offer the technology.

Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology

Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026

141% year-over-year scan volume growth in first half of 2026 Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA Healthcare to secure insurance coverage for Nociscan in the U.S. Continued progress toward the CLARITY trial readout with the addition of multiple new trial sites Strengthened intellectual property position with the addition of a new AI focused patent bringing total issued and pending patents to 65 worldwide Strong balance sheet with $16.3M cash and no debt as of June 30, 2026 BROOMFIELD, Colo., July 29, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the company's recent momentum and value creating priorities through the first half of 2026.

Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026

Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan's Growing Role in Real-World Clinical Practice

Abstracts presented at American Society of Pain & Neuroscience (ASPN) annual meeting across surgical decision support and basivertebral nerve ablation Early findings from real-world evidence study demonstrate immense utility and ability of Nociscan to be incorporated into clinical practice Case study represents first reported use of Nociscan to guide basivertebral nerve ablation in a patient without classic Modic changes on standard MRI, resulting in 95% relief of long-standing chronic low back pain BROOMFIELD, Colo., July 21, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the presentation of two abstracts featuring Nociscan® at the American Society of Pain & Neuroscience (ASPN) Annual Meeting in Miami, Florida.

Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan's Growing Role in Real-World Clinical Practice

Aclarion Announces Texas Spine Care Center as New CLARITY Site

Texas Spine Care Center is a high-volume orthopedic spine practice with a philosophy of understanding the exact source of a patient's pain before recommending treatment CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., July 07, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced Texas Spine Care Center as a new clinical site in its CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial.

Aclarion Announces Texas Spine Care Center as New CLARITY Site

Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub

BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that it will be presenting at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub on Wednesday, June 17, 2026 at 8:30 AM PT at the Bellagio Resort & Hotel.

Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain. Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan volume growth in step with reduced market access barriers BROOMFIELD, Colo.

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

See News Rankings

Price charts implemented using Lightweight Charts™